Anthony  D'Adamio net worth and biography

Anthony D'Adamio Biography and Net Worth

SVP of Bioventus

Tony D’Adamio is Senior Vice President and General Counsel of Bioventus. He has nearly 30 years of senior legal executive experience with diagnostic, health care data and clinical service companies. Tony is responsible for all general and corporate legal matters as well as the ethics and compliance functions at Bioventus.

Prior to joining the company, he served as General Counsel & Secretary of Siemens Medical Solutions and earlier was Deputy General Counsel & Secretary of Siemens Healthcare Diagnostics. He also spent five years as Senior Counsel within the Diagnostics Division of Bayer Healthcare, prior to the acquisition of this business by Siemens. Tony began his legal career at the law firm of Bond, Schoeneck & King before taking corporate legal positions with companies including Group Health Incorporated, Quest Diagnostics and Covance.

He received his Juris Doctor cum laude from Howard University School of Law and a Bachelor of Arts from the State University of New York at Binghamton.

What is Anthony D'Adamio's net worth?

The estimated net worth of Anthony D'Adamio is at least $1.13 million as of April 11th, 2025. Mr. D'Adamio owns 131,416 shares of Bioventus stock worth more than $1,132,806 as of March 13th. This net worth evaluation does not reflect any other investments that Mr. D'Adamio may own. Learn More about Anthony D'Adamio's net worth.

How do I contact Anthony D'Adamio?

The corporate mailing address for Mr. D'Adamio and other Bioventus executives is 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, NC, 27703. Bioventus can also be reached via phone at (919) 474-6700 and via email at [email protected]. Learn More on Anthony D'Adamio's contact information.

Has Anthony D'Adamio been buying or selling shares of Bioventus?

Anthony D'Adamio has not been actively trading shares of Bioventus over the course of the past ninety days. Most recently, Anthony D'adamio sold 2,958 shares of the business's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $7.57, for a transaction totalling $22,392.06. Following the completion of the sale, the senior vice president now directly owns 131,416 shares of the company's stock, valued at $994,819.12. Learn More on Anthony D'Adamio's trading history.

Who are Bioventus' active insiders?

Bioventus' insider roster includes John Bartholdson (Director), Katrina Church (SVP), Robert Claypoole (CEO), Anthony D'Adamio (SVP), P III (CEO), Michelle Mcmurry-Heath (Director), Guy Nohra (Director), Kenneth Reali (CEO), Mark Singleton (Sr. VP), and Mark Singleton (CFO). Learn More on Bioventus' active insiders.

Are insiders buying or selling shares of Bioventus?

During the last twelve months, insiders at the sold shares 7 times. They sold a total of 53,031 shares worth more than $427,812.14. The most recent insider tranaction occured on March, 11th when Director Michelle Mcmurry-Heath sold 12,000 shares worth more than $105,480.00. Insiders at Bioventus own 33.0% of the company. Learn More about insider trades at Bioventus.

Information on this page was last updated on 3/11/2026.

Anthony D'Adamio Insider Trading History at Bioventus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/11/2025Sell2,958$7.57$22,392.06131,416View SEC Filing Icon  
2/18/2025Sell4,380$10.19$44,632.20118,178View SEC Filing Icon  
6/21/2024Sell5,904$5.57$32,885.2895,576View SEC Filing Icon  
6/17/2024Sell11,308$5.84$66,038.7281,630View SEC Filing Icon  
4/11/2024Sell3,054$4.75$14,506.5058,242View SEC Filing Icon  
3/15/2024Sell3,125$5.46$17,062.5051,371View SEC Filing Icon  
3/15/2023Sell3,409$1.39$4,738.5145,610View SEC Filing Icon  
4/4/2022Sell16,016$11.19$179,219.04148,309View SEC Filing Icon  
2/14/2022Sell1,294$11.99$15,515.06View SEC Filing Icon  
See Full Table

Anthony D'Adamio Buying and Selling Activity at Bioventus

This chart shows Anthony D'adamio's buying and selling at Bioventus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bioventus Company Overview

Bioventus logo
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $8.62
Low: $8.56
High: $8.79

50 Day Range

MA: $8.25
Low: $7.57
High: $9.10

2 Week Range

Now: $8.62
Low: $5.81
High: $10.13

Volume

286,351 shs

Average Volume

334,578 shs

Market Capitalization

$716.75 million

P/E Ratio

26.12

Dividend Yield

N/A

Beta

0.78